PlexusDx's $99 genetic test identifies variants in GLP1R (rs6923761) and other peptide pathways that influence how your body absorbs and responds to semaglutide injections
Extensive clinical trials have reinforced the effectiveness of semaglutide, showcasing its potential in achieving meaningful weight reduction in overweight or obese individuals
Is IV therapy suitable for everyone
This resistance, researchers write, likely stems from concerns regarding high annual costs and the lack of immediate ROI. About 60% of survey respondents are not considering changes to their GLP-1 coverage in the near term, researchers say, suggesting these organizations are either satisfied with their current restrictive posture or are being intentional about changing plans until more data emerges about both costs and health outcomes
Liu YL, Ford HE, Druce MR et al (2010) Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents
The entire image processing procedure is summarized in Extended Data Fig